Entera Bio Ltd
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
ENTX$3.25+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Shareholders' Equity
(U.S. dollars in thousands, except share and per share data)
| Ordinary shares | ||||||
|---|---|---|---|---|---|---|
| Number of shares issued | Amounts | Additional paid-in capital | Accumulated other Comprehensive income | Accumulated deficit | Total | |
| BALANCE AT JANUARY 1, 2022 | 28,804,411 | * | 104,950 | 41 | (82,426) | 22,565 |
| Net loss | - | - | - | - | (13,071) | (13,071) |
| Exercise of options to ordinary shares | 5,511 | * | 13 | - | - | 13 |
| Share-based compensation | - | - | 2,247 | - | - | 2,247 |
| BALANCE AT DECEMBER 31, 2022 | 28,809,922 | * | 107,210 | 41 | (95,497) | 11,754 |
| Net loss | - | - | - | - | (8,889) | (8,889) |
| Issuance of ordinary shares, warrants and pre-funded warrants due to a private placement, net of issuance costs | 6,662,389 | 1 | 5,826 | - | - | 5,827 |
| Issuance of shares under the ATM program, net of issuance costs | 4,030 | * | 5 | - | - | 5 |
| Share-based compensation | - | - | 1,689 | - | - | 1,689 |
| BALANCE AT DECEMBER 31, 2023 | 35,476,341 | 1 | 114,730 | 41 | (104,386) | 10,386 |
- Represents an amount less than one thousand US dollars.
The accompanying notes are an integral part of these consolidated financial statements.
CONSOLIDATED STATEMENTS OF CASH FLOWS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.